Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2013

View Archived Issues

Novel protease inhibitors exhibit broad-spectrum antiviral activity

A potential new biomarker for predicting recurrence of HCC

Exelixis describes discovery of a novel small-molecule mTOR inhibitor

AbbVie initiates phase III renal outcomes study of atrasentan in diabetic nephropathy

RaQualia reports data from first-in-human study of RQ-00000010

Grant supports development of Metabolomic Technologies' colonic polyp screening test

Pasireotide may have potential in treatment of postoperative dumping syndrome

Mucosis presents preclinical SynGEM data

Actavis to acquire Warner Chilcott

Baxter obtains marketing approval in Europe for HyQvia

Biogen Idec submits BLA to FDA for Plegridy in multiple sclerosis

Grifols and Aradigm agree for Pulmaquin and possible partial stock adquisition

Intercell obtains approval for Ixiaro in pediatric patients in the U.S.

New orexin OX2 receptor antagonists prepared at Merck & Co.

KineMed and MedImmune to study protein dynamics in neurodegenerative diseases

Galderma presents new CXCR2 receptor antagonists

Liquidia Technologies extends collaboration with PATH

Pharmaxis meets with the FDA regarding path to approval for Bronchitol

Merck & Co. synthesizes novel ROMK blockers

Sorrento Therapeutics receives continued NIAID support

New mGlu receptor modulators divulged by Merck & Co.

Recombinant LCAT replacement therapy mobilizes excess cholesterol from tissue in vivo

UCB and IBM collaborate on personalize care for epilepsy

NicOx patents new nitric oxide donors

Chinese researchers patent new tyrosine-protein kinase inhibitors

EMA grants accelerated assessment to Gilead's MAA for sofosbuvir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 2, 2025.
Unnatural Products joins Argenx in a $1.5B macrocyclic deal
BioWorld
Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
CMS eyes competitive bidding for CGMs, insulin pumps
BioWorld MedTech
The U.S. Centers for Medicare & Medicaid Services posted the draft home health rule for calendar year 2026, which includes a proposal to subject continuous...